- Home
- MYGN vs TXO Comparison
MYGN vs TXO Comparison
Compare MYGN & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TXO
- Stock Information
- Founded
- MYGN 1991
- TXO 2012
- Country
- MYGN United States
- TXO United States
- Employees
- MYGN N/A
- TXO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TXO Oil & Gas Production
- Sector
- MYGN Health Care
- TXO Energy
- Exchange
- MYGN Nasdaq
- TXO Nasdaq
- Market Cap
- MYGN 744.7M
- TXO 699.0M
- IPO Year
- MYGN 1995
- TXO 2023
- Fundamental
- Price
- MYGN $4.13
- TXO $15.20
- Analyst Decision
- MYGN Hold
- TXO
- Analyst Count
- MYGN 16
- TXO 0
- Target Price
- MYGN $16.40
- TXO N/A
- AVG Volume (30 Days)
- MYGN 3.4M
- TXO 331.3K
- Earning Date
- MYGN 05-06-2025
- TXO 05-01-2025
- Dividend Yield
- MYGN N/A
- TXO 15.89%
- EPS Growth
- MYGN N/A
- TXO N/A
- EPS
- MYGN N/A
- TXO 0.40
- Revenue
- MYGN $831,300,000.00
- TXO $299,696,000.00
- Revenue This Year
- MYGN N/A
- TXO $19.72
- Revenue Next Year
- MYGN $7.21
- TXO N/A
- P/E Ratio
- MYGN N/A
- TXO $37.60
- Revenue Growth
- MYGN 7.38
- TXO 3.43
- 52 Week Low
- MYGN $3.98
- TXO $15.22
- 52 Week High
- MYGN $29.30
- TXO $23.56
- Technical
- Relative Strength Index (RSI)
- MYGN 25.47
- TXO 30.99
- Support Level
- MYGN $3.81
- TXO $14.99
- Resistance Level
- MYGN $4.31
- TXO $17.90
- Average True Range (ATR)
- MYGN 0.47
- TXO 0.49
- MACD
- MYGN -0.16
- TXO -0.11
- Stochastic Oscillator
- MYGN 8.00
- TXO 7.11
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.